Background MicroRNA expression profiles can be used to distinguish normal B cells from
malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated …

Progress in understanding the biology of multiple myeloma (MM), a plasma cell malignancy,
has been slow. The discovery of microRNAs (miRNAs), a class of small noncoding RNAs …

In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely
detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence that …

MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of
gene expression. To determine whether miRNAs are associated with cytogenetic …

p53 suppresses tumor progression and metastasis. Epithelial–mesenchymal transition (EMT)
is a key process in tumor progression and metastasis. The transcription factors ZEB1 and …

Lung and liver cancers are among the most deadly types of cancer. Despite improvements
in treatment over the past few decades, patient survival remains poor, underlining the need …

Noncoding RNA (ncRNA) transcripts are thought to be involved in human tumorigenesis. We
report that a large fraction of genomic ultraconserved regions (UCRs) encode a particular …

microRNAs are a highly conserved class of noncoding RNAs with important regulatory
functions in proliferation, apoptosis, development, and differentiation. To discover novel …

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface
receptor CD38, which is expressed not only on plasma cells but also on NK cells and …

We studied miRNA profiles in 4419 human samples (3312 neoplastic, 1107 nonmalignant),
corresponding to 50 normal tissues and 51 cancer types. The complexity of our database …